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Abstract 
Context. Advanced lung cancer patients typically have a poor prognosis and many symptoms 
that interfere with functioning, contributing to high rates of emotional distress in both patients 
and family caregivers. There remains a need for evidence-based interventions to improve 
functional outcomes and distress in this population. 
Objectives. This pilot trial examined the feasibility and preliminary efficacy of telephone-based 
Acceptance and Commitment Therapy (ACT) for symptomatic, advanced lung cancer patients 
and their distressed family caregivers. Primary outcomes were patient symptom interference with 
functioning and patient and caregiver distress. 
Methods. Symptomatic, advanced lung cancer patients and distressed caregivers (n=50 dyads) 
were randomly assigned to six sessions of ACT or an education/support condition. Patients 
completed measures of symptom interference and measures assessing the severity of fatigue, 
pain, sleep disturbance, and breathlessness. Patients and caregivers completed measures of 
distress and illness acceptance and struggle. 
Results. The eligibility screening rate (51%) and retention rate (76% at 6 weeks post-
intervention) demonstrated feasibility. No group differences were found with respect to patient 
and caregiver outcomes. Both groups showed a small, significant decrease in struggle with the 
illness over the study period, but did not show meaningful change in other outcomes. 
Conclusion. Findings suggest that telephone-based ACT is feasible for many advanced lung 
cancer patients and caregivers, but may not substantially reduce symptom interference and 
distress. Low baseline levels of certain symptoms may have contributed to null findings. Next 
steps include applying ACT to specific, clinically meaningful symptom interference and varying 
intervention dose and modality. 
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Introduction 
 Lung cancer is one of the most common cancers affecting men and women (1). The 
majority of lung cancer patients are diagnosed with regional or distant stage disease (1), resulting 
in various distressing symptoms (2, 3). The most prevalent symptoms in lung cancer patients 
include fatigue, sleep disturbance, pain, breathlessness, depressive symptoms, and anxiety (2, 4, 
5). These symptoms often co-occur and have been associated with impaired daily activities and 
quality of life (QoL) (6-8). 
 Family caregivers also experience QoL impairment (9-11). As many as 50% of family 
caregivers of lung cancer patients report clinically meaningful anxiety or depressive symptoms 
(12-15). Caregiver distress may be related to the patient’s poor prognosis, high symptom burden, 
and attributions of blame or stigma associated with the patient’s tobacco use (16-19). 
Additionally, caregivers of lung cancer patients have reported challenges in performing 
caregiving tasks, such as monitoring symptoms (17, 20, 21).  
  Growing evidence suggests that the early integration of standard oncologic and palliative 
care may improve QoL and possibly survival in advanced lung cancer patients and reduce 
caregiver distress (22-24). Based on this evidence, clinical practice guidelines now emphasize 
this integration in lung cancer care (25, 26). However, non-pharmacological aspects of palliative 
care for lung cancer patients and caregivers have mixed empirical support (27-30). One pilot trial 
found that a telephone-based dyadic intervention for advanced lung cancer patients and 
caregivers reduced anxiety and depressive symptoms compared to usual care (31). Another pilot 
trial compared a telephone-based dyadic intervention for symptomatic lung cancer patients of 
mixed stages and caregivers to an education/support condition (32). Patient physical and 
psychological symptoms and caregiver psychological symptoms did not significantly change 
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over time in either study condition. A third larger telephone-based trial for early-stage lung 
cancer patients and caregivers found that both caregiver-assisted coping skills training and 
education/support resulted in improved patient depression, lung cancer symptoms, and caregiver 
anxiety (33). Thus, there remains a need to develop innovative interventions for advanced, 
symptomatic lung cancer patients and caregivers. 
 One intervention that shows promise for reducing symptom-related suffering in cancer is 
Acceptance and Commitment Therapy (ACT) (34, 35). In contrast to traditional cognitive-
behavioral therapy (CBT) that aims to reduce symptoms and change maladaptive thoughts (32, 
33), the goal of ACT is to increase psychological flexibility so that difficult thoughts, feelings, 
and symptoms interfere less with meaningful activities (36). Psychological flexibility is defined 
as full awareness of the present moment while engaging in action consistent with deeply held 
values (37). According to the ACT model, six psychological skills—mindfulness, perspective-
taking, cognitive defusion, acceptance, value clarification, and committed action—facilitate 
psychological flexibility (35, 37).  
 ACT has a strong evidence base in chronic pain (38, 39) and mental health (40) and has 
been tested in several pilot randomized controlled trials (RCTs) with cancer patients (41-43). 
One RCT with late-stage ovarian cancer patients found that ACT produced large improvement in 
anxiety and depressive symptoms compared to CBT (42). Another pilot RCT with metastatic 
breast cancer patients found that ACT showed promise relative to an education/support condition 
with respect to fatigue interference with activities, mood, and cognition (43). ACT has yet to be 
applied to cancer caregivers. 
 We developed an ACT intervention with the goal of reducing symptom interference (i.e., 
the degree to which symptoms interfere with activities, mood, and cognition) in advanced lung 
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cancer patients and patient and caregiver distress. The intervention included the following 
components: mindfulness practices; acceptance of thoughts, feelings, and physical symptoms 
through metaphors and experiential exercises; clarification of personal values; and taking action 
steps consistent with these values. We tailored the intervention to the experiences of advanced 
lung cancer patients and caregivers and delivered it via phone to improve accessibility.  
 This pilot trial examined the feasibility and preliminary efficacy of ACT compared to an 
education/support condition that controlled for time and attention. We recruited advanced lung 
cancer patients who reported moderate to severe bother for at least one of six common symptoms 
(i.e., fatigue, sleep disturbance, pain, breathlessness, depressive symptoms, or anxiety) and their 
family caregivers with elevated distress. Feasibility was evaluated via recruitment, retention, and 
session completion rates. Preliminary efficacy was evaluated via ACT’s effect on patient 
symptom interference (i.e., global symptom interference, fatigue interference, pain interference, 
and dyspnea task avoidance) and patient and caregiver distress relative to the education/support 
condition. Although symptom reduction is not the emphasis of ACT, this intervention has 
resulted in reduced symptoms in trials with medical populations, including cancer patients (34, 
40). Thus, we compared the two interventions regarding the severity of patient fatigue, pain, 
sleep disturbance, and breathlessness. We also examined whether ACT improved patient and 
caregiver acceptance of the illness and reduced their sense of struggle with the illness. 
Methods 
Participants 
Patient eligibility criteria were 1) a diagnosis of advanced lung cancer (i.e., stage III or IV 
non-small cell or extensive stage small cell lung cancer) at least 3 weeks before enrollment; 2) 
moderate to severe bother for at least one symptom, defined as a Rotterdam Symptom item score 
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>2 on a 1-4 scale for fatigue, pain, sleep disturbance, breathlessness, depressive symptoms, or 
worry (44); and 3) a consenting primary family caregiver. Patients were ineligible if they 1) had 
severe cognitive impairment (i.e., 3 or more errors on a six-item cognitive screener) (45), 2) had 
a self-reported Eastern Cooperative Oncology Group (ECOG) score >2 (able to do little activity) 
(46, 47), or 3) were receiving hospice care at the time of enrollment. Eligible caregivers lived 
with the patient or had visited the patient at least twice a week for the past month. n addition, 
eligible caregivers showed clinical or subclinical distress, defined as a T-score >55 on either the 
4-item Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety or 
depression measure (48) or a Distress Thermometer score >3 (49). Both patients and caregivers 
had to be adults (>18 years of age) who were fluent in English.  
Procedures 
Participants were recruited from the Indiana University (IU) Health Simon Cancer Center 
and other IU Health sites between October 2016 and November 2017. Study procedures were 
approved by the IU institutional review board. Initial patient eligibility was confirmed through 
chart review and consultation with the oncologist. Trained research assistants approached 
patients during an oncology clinic visit or through letters of invitation and telephone calls to 
describe the study. Interested patients identified their primary family caregiver and were 
screened for eligibility. If patients consented to participate, caregivers were approached in clinic 
or through telephone calls for eligibility screening and consent.   
Participants completed individual baseline telephone assessments and were randomly 
assigned to either the ACT or education/support condition. Randomization was performed by a 
person who did not interact with participants using a SAS procedure and was stratified by patient 
gender and performance status (self-reported ECOG scores 0 or 1 vs. 2) (46). Research assistants 
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blind to study condition administered individual telephone assessments at 2 and 6 weeks post-
intervention, and each person received a $25 gift card per assessment.   
Measures 
Primary Outcomes. The primary outcome of patient symptom interference with 
functioning was assessed with the following measures: (1) 6-item global symptom interference 
subscale of the MD Anderson Symptom Inventory (50), (2) 7-item interference subscale of the 
Fatigue Symptom Inventory (51), (3) 4-item PROMIS scale for pain interference (52), and (4) 
one PROMIS item assessing task avoidance related to dyspnea (53, 54). The primary outcome of 
patient and caregiver distress was assessed with the 4-item PROMIS anxiety and depression 
measures (48) and the 1-item Distress Thermometer (49). 
Secondary Outcomes. The following measures assessed the severity of patient physical 
symptoms: (1) the 4-item PROMIS fatigue measure, (2) the 4-item PROMIS sleep disturbance 
measure, and (3) the 3-item PROMIS pain intensity measure (53, 54). In addition, patient 
breathlessness was evaluated with four items from the Memorial Symptom Assessment Scale 
(55). Finally, patient and caregiver acceptance of the illness was measured with the PEACE 
questionnaire, which includes a 7-item Struggle with Illness subscale and a 5-item Peaceful 
Acceptance subscale (56). 
Sociodemographics and Medical Variables. Patients and caregivers reported their 
demographic characteristics and mental health service use at baseline. Patient medical 
information was obtained via chart review. 
General Aspects of Treatment Procedures and Therapist Training  
Participants in both study conditions participated in six weekly 50-minute telephone 
sessions. Prior trials with advanced cancer patient-caregiver dyads support the feasibility of six 
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sessions (31, 57). Patients and caregivers completed sessions 1 and 4-6 together via 
speakerphone, whereas sessions 2 and 3 were delivered to patients and caregivers separately. 
Holding both dyadic and individual sessions allowed the therapist to meet the shared and unique 
needs of patients and caregivers. All sessions were audiorecorded. The ACT condition was 
delivered by a master’s level social worker with experience in ACT, whereas the 
education/support condition was delivered by a Ph.D. student in clinical psychology with 
experience in psychoeducation. The therapists were trained and supervised on a weekly basis by 
two psychologists. Training included didactics and role-plays of treatment sessions detailed in 
manuals. Fidelity checklists were developed for both study conditions, and one of the 
psychologists randomly selected 18% of audio recordings to review for adherence to the 
manuals. The average fidelity rating was 96%. Both psychologists provided feedback on 
treatment adherence and quality.  
Acceptance and Commitment Therapy 
The ACT intervention targeted all processes of the ACT model of behavior change, 
including mindfulness, perspective taking, cognitive defusion, acceptance, values clarification, 
and committed action (35, 37). The intervention emphasized developing mindfulness skills and 
engaging in actions aligned with personal values. For example, many patients cope with 
symptoms by engaging in more rest and attempting to avoid symptom experiences – 
unfortunately, these well-intended coping strategies often lead patients to withdraw from valued 
activities. ACT supports patients’ feasible engagement in these activities. Additionally, patients 
and caregivers applied ACT skills to difficult thoughts and feelings. Each patient and caregiver 
was mailed handouts summarizing session topics and a CD that our team developed to guide 
mindfulness practices. Table 1 provides a summary of the intervention components. 
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 During the first session, the therapist asked about the dyad’s background, the patient’s 
strategies for managing symptoms, and the caregiver’s strategies for managing their own 
difficult thoughts and feelings. In addition, the concept of mindfulness was introduced. Across 
the six sessions, patients and caregivers practiced various mindfulness exercises, clarified their 
values, and set committed action steps aligned with their values. During each session, the 
therapist assessed participants’ home practice of mindfulness and other skills and concluded with 
a discussion of practice for the upcoming week. Although each participant learned the same 
skills, in-session and home practices were tailored to their cancer or caregiving-related 
experiences and other challenges. For example, barriers to committed action steps were 
discussed. In addition, the mindfulness exercises did not focus on the breath, as breathing 
difficulties are associated with panic symptoms in many lung cancer patients (58). 
Education/Support Condition 
Similar to other psychosocial intervention trials for cancer patient-caregiver dyads (32, 
59), the comparison group was an education/support condition. The intervention involved 
supportive listening and directing patients and caregivers to resources for practical and health 
information and psychosocial support. Table 1 presents a summary of the education/support 
components. The sessions included an orientation to the medical center and treatment team, 
education regarding common QoL concerns experienced by patients and caregivers, and 
discussion of resources for psychosocial support, health information, and financial assistance. 
The therapist also provided tips for critically evaluating health information in books, magazines, 
and websites. Each patient and caregiver was mailed handouts summarizing session topics and 
was asked to review them at home. Sessions were not tailored to participants, except for the 
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omission of topics that did not apply to them. Although both study therapists engaged in 
supportive listening, specific intervention content did not overlap across study conditions. 
Statistical Analyses 
Descriptive statistics were computed to examine feasibility. The assumptions of 
normality and linearity were examined for each continuous variable. After applying a 
winsorization transformation to outliers on depressive symptoms, anxiety, and acceptance of 
illness variables, all skewness and kurtosis values were acceptable (60). Baseline comparisons of 
study conditions were conducted for patients and caregivers separately using t-tests (or Fisher’s 
exact tests). Potential gender differences were evaluated. Linear mixed-model repeated-measures 
analyses in SPSS were used to examine the preliminary efficacy of ACT. These analyses are an 
intent-to-treat approach because they use all available data. Multi-level modeling for dyadic data, 
an approach that accounts for the non-independence of data from members of the same dyad, 
was used for outcomes reported by patients and caregivers (61, 62). Models included the main 
effects of study group, time, and role (patient or caregiver) and all interaction effects (e.g., group 
x time, group x time x role). Both study group and time were categorical variables in these 
models in order to focus the analyses on mean differences across groups and time. Treatment 
effects are evidenced by a significant interaction between study group and time. A significant 
group x time x role interaction indicates that the treatment effects differ between patients and 
caregivers. For outcomes that only patients or caregivers reported, models included the main 
effects of study group and time and the group x time interaction. For each analysis, the partial 
correlation coefficient (pr), an effect size statistic, was computed using the F value and degrees 
of freedom (63). Two-sided p-values < .05 were considered statistically significant.   
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At baseline, seven patient outcomes, but none of the caregiver outcomes, varied by 
gender (data not shown). When patient gender was included in the multi-level models as a 
potential moderator of treatment effects, none of the moderation findings were significant (data 
not shown). 
Results 
Feasibility 
Of the 331 advanced lung cancer patients who were approached, 134 declined to 
participate, 51 were ineligible, 60 could not be reached via phone, and 86 consented (see Figure 
1). Patients agreeing to the eligibility screening did not differ from refusers with respect to race 
or age (ps>.05). However, male patients were more likely than female patients to agree to 
screening, χ2(1, N=239)=4.43, p<.05. Of the 86 caregivers who were approached, 3 declined 
participation, 24 were ineligible, and 4 could not be reached via phone. Thus, 55 dyads were 
eligible and consented to participate. Primary reasons for refusal were lack of interest, time 
constraints, and health. Five dyads withdrew prior to randomization because of lack of interest, 
medical reasons, or loss to follow-up. Twenty-five of the remaining 50 dyads were randomized 
to the ACT intervention, and 25 were randomized to the education/support intervention. Most 
dyads (39/50, 78%) completed all six sessions and were retained at 6-week follow-up (38/50, 
76%).   
Participant Characteristics 
 Table 2 presents participant characteristics by study group and group comparisons at 
baseline. The majority of patients (56%) were men and most caregivers (80%) were women. 
Patients and caregivers were primarily White and had an average of 14 years of education. A 
range of income levels were represented. The majority of caregivers (72%) were spouses or 
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partners of the patient. Demographics, medical factors, and outcome variables did not vary by 
study condition at baseline, with the exception of caregiver age.  
Preliminary Efficacy 
Primary Outcomes. Results of the mixed-effects model analyses showed no group x time 
effects on indicators of patient symptom interference (i.e., global symptom interference, fatigue 
interference, pain interference, and dyspnea task avoidance; Table 3). Effect sizes for these group 
x time effects were small (prs=.02-.10). In addition, mixed-model analyses showed no group x 
time effects for patient or caregiver depressive symptoms, anxiety, and general distress (prs=.02-
.05). There were also no significant main effects of time, suggesting that primary outcome 
variables did not change on average during the study period. Although there was a significant 
group x time x role interaction for general distress (pr=.21), mean changes in general distress 
from baseline were small at both follow-ups, irrespective of study group and role.  
Secondary Outcomes. Mixed model analyses showed no group x time effects on patient 
physical symptom severity (i.e., fatigue, pain, sleep disturbance, and breathlessness; Table 3), 
with effect sizes in the small range (prs=.04-.13). In addition, there were no group x time effects 
on patient and caregiver struggle with illness and illness acceptance (prs=.12 and .08, 
respectively; Table 3). However, there was a significant main effect of time on struggle with 
illness (pr=.26), indicating that participants in both groups, on average, reported a small decrease 
in struggle with illness over the study period. Additionally, there was a significant main effect of 
role on illness acceptance, such that patients, on average, had higher levels than caregivers 
(pr=.38). 
Discussion 
 This trial is the first to examine ACT for cancer patient-caregiver dyads and the first to 
test ACT for those coping with lung cancer. The strong recruitment rate (51%) and retention at 
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6-weeks post-intervention (76%) support intervention feasibility. Researchers have documented 
challenges in recruiting and retaining lung cancer patients, given their high symptom burden 
(64). Our recruitment and retention rates were comparable to those of couple-based intervention 
trials in cancer, most of which targeted dyads coping with non-metastatic disease (27).  
Preliminary evidence of ACT’s efficacy was not obtained. Compared to the 
education/support condition, ACT did not lead to reduced patient symptom interference with 
functioning or reduced patient or caregiver distress. In addition, compared to education/support, 
ACT did not reduce the severity of patient fatigue, pain, sleep disturbance, or breathlessness. 
ACT also did not improve patient and caregiver illness acceptance and struggle. Both groups 
reported a small, significant decrease in struggle with the illness over the study period, but did 
not show meaningful change in other study outcomes.  
 Our findings are partially consistent with those of prior intervention trials for cancer 
dyads. Indeed, two other telephone-based psychosocial intervention trials with lung cancer dyads 
found no treatment effect relative to an education/support condition (32, 33). However, 
comparisons across trials with lung cancer dyads should be made with caution, given differences 
in eligibility criteria (e.g., cancer stage, symptoms), intervention dose (range=4-14 sessions), and 
format (e.g., focus on patient vs. dyad) (31-33). The comparison group might also affect results, 
as evidenced by previous large effects of a telephone intervention on advanced lung cancer 
dyads’ distress compared to usual care (31).  
 Several factors might account for the current findings. First, participants reported 
relatively good functioning at baseline. Thus, most outcomes had, on average, moderate room for 
improvement over the study period, which may have limited our ability to detect intervention 
effects. Additionally, similar to the general population of lung cancer patients (65), many 
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participants in our trial had low incomes. Stressors related to socioeconomic disadvantage may 
have been a greater focus for some participants than the intervention sessions’ content. However, 
neither study group showed worsening symptom and distress outcomes over time. Because we 
did not include a usual care condition, we do not know if this group would have shown 
worsening outcomes over time relative to ACT and education/support.  
 Finally, the brevity of the intervention and telephone delivery might have reduced 
intervention effects. To date, meta-analyses of psychosocial interventions for cancer caregivers 
and cancer patient-caregiver dyads have found mixed evidence of associations between 
intervention dose and study outcomes (27, 29). The current number of sessions is similar to most 
couple-based interventions in cancer (27). There is also no evidence that the phone modality is 
inferior to in-person treatment, but these modalities have rarely been compared (29).    
Several potential directions for future research may build on the growing ACT literature 
in cancer and other chronic illnesses. First, researchers should consider enrolling patients with a 
specific symptom that interferes with functioning and targeting this interference in ACT. 
Applying ACT skills to a specific, clinically meaningful problem may maximize intervention 
efficacy. Second, research is needed to elucidate mechanisms underlying beneficial effects of 
ACT on health outcomes found in previous trials (34, 40). For example, if mindfulness or values-
based action is driving the health effects of ACT, then these components could be emphasized in 
future trials. Finally, while this trial included both dyadic and individual sessions, future research 
may directly compare these approaches. 
 Limitations of the study warrant mention. The sample was primarily White and recruited 
from medical centers in Indiana, thereby limiting the generalizability of the findings. 
Additionally, patients with moderate symptom bother and caregivers with subclinical distress 
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were eligible, which may have led to smaller intervention effects. It is unclear whether male 
patients’ higher rates of eligibility screening compared to female patients affected trial results. 
Finally, the sample size reduced statistical power. However, the goal of this pilot study was to 
determine intervention feasibility and generate estimates of effects for a larger, fully-powered 
trial. 
 This trial and other pilot ACT trials (41-43) support ACT’s feasibility for many cancer 
patients and caregivers. Larger trials are needed before drawing conclusions regarding ACT’s 
impact on functioning and distress in this population and moderators of its effects. These trials 
could also assess ACT’s impact on value-based action, social outcomes, and clinical decisions 
and the potential benefits of increasing the intervention dose. Subsequently, implementation 
studies could examine flexible treatment delivery methods. Given the high symptom burden 
associated with advanced lung cancer (2, 3, 18, 19), testing novel psychosocial interventions for 
these patients and caregivers should be a high priority for future research. 
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Table 1. Summary of Topics Covered in Each Intervention Condition 
 
Acceptance and Commitment Therapy 
 
Education/Support 
• Discuss patient and caregiver coping 
strategies for managing symptoms 
and distress, including control vs. 
non-control-based strategies 
• Experiential practice of mindfulness 
during sessions and at home (e.g., 
notice an object/scene, use the 
metaphor of leaves on a stream to 
notice changing thoughts and 
feelings) 
• Practice cognitive defusion-- 
noticing thoughts rather than being 
caught up in thoughts (e.g., 
passengers on the bus metaphor) 
• Cultivate perspective-taking or a 
locus from which to observe and 
accept changing experiences (e.g., 
imagine feelings about a stressful 
situation as a physical object) 
• Identify personal values (e.g., being 
• Orient to the medical center and 
treatment team, provide overview of quality 
of life issues, and discuss physical quality of 
life 
• Discuss social quality of life (e.g., family 
challenges related to cancer, employment) 
and refer to resources 
• Discuss other aspects of quality of life (e.g., 
changes in roles and activities, emotional and 
cognitive functioning) and refer to resources 
• Discuss financial challenges and resources 
for managing them 
• Describe and practice methods for evaluating 
health information in books, magazines, and 
websites 
• Review previous sessions and refer to 
websites with cancer-related information 
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a loving partner, engaging in 
spiritual practices) 
• Plan and practice values-consistent 
actions, despite symptoms or distress 
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Table 2. Patient and Caregiver Characteristics and Group Comparisons at Baseline 
 Patients  
(n = 50) 
 Caregivers 
(n = 50) 
 
 
 
Characteristics 
 
ACT  
(n = 25) 
Education/ 
Support 
(n = 25) 
t-test/ 
Fisher’s 
Exact Test p 
 
ACT  
(n = 25) 
Education/ 
Support 
(n = 25) 
t-test/ 
Fisher’s 
Exact Test p 
Sex, n (%)   1.00   0.73 
    Male 14 (56.00) 14 (56.00)   6 (24.00) 4 (16.00)  
    Female 11 (44.00) 11 (44.00)  19 (76.00) 21 (84.00)  
Age   0.73   0.04 
    Mean 63.20 62.00  61.64 52.40  
    SD 11.27 13.13  11.52 18.10  
    Range 35 - 81 37 - 82  36 - 83 22 - 78  
Race, n (%)   0.42   0.70 
   Non-Hispanic White 20 (80.00)  23 (92.00)  20 (80.00) 22 (88.00)  
Employment status, n (%)   0.57   0.73 
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    Employed full or part-time   4 (16.00)   7 (28.00)  12 (48.00) 15 (60.00)  
    Retired 14 (56.00) 11 (44.00)  10 (40.00)  7 (28.00)  
    Unemployed   7 (28.00)   6 (24.00)    3 (12.00)  3 (12.00)  
    Missing     0 (0) 1 (4.00)      0 (0)    0 (0)  
Household income, n (%)   0.57   0.66 
    $0 - $50,999  10 (40.00)   8 (32.00)   10 (40.00)  8 (32.00)  
    $51,000 - $99,999 6 (24.00) 10 (40.00)  7 (28.00)  8 (32.00)  
    $100,000 or more 6 (24.00)   6 (24.00)  5 (20.00)  8 (32.00)  
    Missing 3 (12.00) 1 (4.00)  3 (12.00) 1 (4.00)  
Years of education    0.33   0.56 
    Mean 14.28 13.56  14.44 14.88  
    SD   2.57   2.65    2.57   2.71  
    Range 12 - 20 7 - 18  11 - 19 10 - 21  
Caregiver relationship to the patient, n (%) 
 
    0.75 
   Spouse/partner --- ---  19 (76.00) 17 (68.00)  
   Other family member  --- ---    6 (24.00)   8 (32.00)  
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Caregiver lives with the patient, n (%) --- ---  20 (80.00) 19 (76.00) 1.00 
Married/living with a partner, n (%) 20 (80.00)    18 (72.00) 0.74 21 (84.00) 20 (80.00) 1.00 
Psychiatric medication, n (%)a   9 (36.00)    13 (52.00) 0.39 11 (44.00) 10 (40.00) 1.00 
Psychotherapy/counseling, n (%)a  3 (12.00)      0 (0) 0.24 1 (4.00) 1 (4.00) 1.00 
Study site, n (%)   1.00    
   Indiana University Simon Cancer Center 23 (92.00)   22 (88.00)  --- ---  
   Other Indiana University Health Sites 2 (8.00)    3 (12.00)  --- ---  
Disease stage, n (%)   0.54    
   NSCLC Stage III    5 (20.00)    9 (36.00)  --- ---  
   NSCLC Stage IV 19 (76.00)  15 (60.00)  --- ---  
   SCLC Extensive Stage 1 (4.00)  1 (4.00)  --- ---  
Time since diagnosis in years   0.49    
   Mean 1.79 1.41  --- ---  
   SD 2.03 1.77  --- ---  
   Range 0.14 - 8.30 0.17 - 7.71  --- ---  
Treatments received, n (%)       
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   Chemotherapy  16 (64.00) 15 (60.00) 1.00 --- ---  
   Radiation 10 (40.00)  8 (32.00) 0.77 --- ---  
   Chemoradiation  6 (24.00)  9 (36.00) 0.54 --- ---  
   Surgery to remove primary tumor  4 (16.00)  8 (32.00) 0.32 --- ---  
   Surgery to remove metastases 1 (4.00)    2 (8.00) 1.00 --- ---  
Smoking, n (%)    0.57   0.56 
   Never smoked 7 (28.00)  5 (20.00)   14 (56.00)  12 (48.00)  
   Current smoker 13 (52.00) 17 (68.00)  7 (28.00) 5 (20.00)  
   Former smoker  5 (20.00)  3 (12.00)  4 (16.00) 7 (28.00)  
Patient ECOG scoreb 
 
 0.83    
   Mean 0.96 1.00  --- ---  
   SD 0.69 0.66  --- ---  
   Range 0.00 - 2.00 0.00 - 2.00  --- ---  
Symptom botherc       
   Depressed mood, n (%) 10 (40.00) 10 (40.00) 1.00 --- ---  
   Worrying, n (%) 15 (60.00) 15 (60.00) 1.00 --- ---  
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   Pain, n (%) 15 (60.00) 17 (68.00) 0.77 --- ---  
   Difficulty sleeping, n (%) 13 (52.00) 15 (60.00) 0.78 --- ---  
   Shortness of breath, n (%) 15 (60.00) 13 (52.00) 0.78 --- ---  
   Tiredness, n (%) 20 (80.00) 23 (92.00) 0.42 --- ---  
Number of symptomsd   0.63 --- ---  
    Mean 3.52 3.72  --- ---  
    SD 1.36 1.57  --- ---  
    Range 2.00 - 6.00 1.00 - 6.00  --- ---  
Depressive symptoms, n (%)e --- ---  13 (52.00) 11 (44.00) 0.78 
Anxiety, n (%)e --- ---  18 (72.00)   20 (80.00) 0.74 
General distress, n (%)f --- ---  22 (88.00)   23 (92.00) 1.00 
Note. ACT = Acceptance and Commitment Therapy; SD = standard deviation; NSCLC = non-small cell lung cancer; SCLC = small 
cell lung cancer; ECOG = Eastern Cooperative Oncology Group. 
aTreatment received in the past month at baseline. 
bAssessed at screening.  
cScore of 2 or higher (moderate to severe symptom bother) on Rotterdam Symptom Checklist items at screening.   
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dNumber of Rotterdam Symptom Checklist items with scores of 2 or higher (moderate to severe symptom bother) at screening. 
eT-score of 55 (one-half standard deviation above the population mean) or higher on 4-item PROMIS measure at screening.   
fDistress Thermometer score of 3 or higher indicating clinical or subclinical distress at screening.   
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Table 3. Intent-to-Treat Results for Multilevel Linear Models Predicting Outcomes (N = 50 Dyads) 
 ACT Education/Support     
 Baseline 
2 Weeks 
Post-
intervention 
6 Weeks 
Post-
intervention Baseline 
2 Weeks 
Post-
intervention 
6 Weeks 
Post-
intervention    
 
Outcome Fixed Effect Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) df F P Pr 
Primary Outcomes:           
Patient global symptom 
interference  
3.07 (0.56) 2.96 (0.59) 2.98 (0.59) 2.81 (0.56) 3.39 (0.62) 3.47 (0.61)     
   Group       45 0.09 0.76 0.05 
   Time       73 0.38 0.69 0.07 
   Group x time       73 0.68 0.51 0.10 
Patient fatigue interference 2.65 (0.50) 2.73 (0.53) 2.83 (0.53) 2.60 (0.50) 2.79 (0.55) 2.76 (0.54)     
   Group       49 0.00 0.98 0.00 
   Time       77 0.18 0.83 0.05 
   Group x time       77 0.03 0.97 0.02 
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Patient pain interference 9.12 (0.94) 8.46 (1.00) 8.21 (1.00) 8.12 (0.94) 7.45 (1.03) 7.66 (1.03)     
   Group       48 0.50 0.48 0.10 
   Time       78 0.83 0.44 0.10 
   Group x time       78 0.09 0.92 0.03 
Patient dyspnea task 
avoidance 
1.08 (0.21) 1.09 (0.23) 0.99 (0.23) 0.80 (0.21) 0.52 (0.24) 0.61 (0.24)     
   Group       46 2.47 0.12 0.22 
   Time       77 0.55 0.58 0.08 
   Group x time       77 0.45 0.64 0.08 
Patient depressive 
symptoms  6.08 (0.65) 6.15 (0.67)  5.92 (0.67) 7.18 (0.65) 6.89 (0.68) 7.05 (0.68) 
    
Caregiver depressive 
symptoms 
6.64 (0.58) 5.80 (0.62) 5.95 (0.62) 7.20 (0.58) 6.20 (0.65) 6.34 (0.65)     
   Group       48 1.03 0.31 0.15 
   Time       78 2.59 0.08 0.18 
   Role       43 0.26 0.61 0.08 
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   Time x role       81 1.23 0.30 0.12 
   Group x time       78 0.15 0.86 0.04 
   Group x role       43 0.53 0.47 0.11 
   Group x time x role       81 0.06 0.94 0.03 
Patient anxiety symptoms  6.36 (0.72) 6.26 (0.74) 5.95 (0.74) 7.69 (0.72) 7.54 (0.76) 7.24 (0.76)     
Caregiver anxiety 
symptoms 7.60 (0.65) 7.23 (0.69) 6.92 (0.69) 8.16 (0.65) 7.68 (0.72) 7.29 (0.72) 
    
   Group       47 1.34 0.25 0.17 
   Time       76 2.48 0.09 0.18 
   Role       48 1.83 0.18 0.19 
   Time x role       81 0.21 0.81 0.05 
   Group x time       76 0.02 0.98 0.02 
   Group x role       48 0.79 0.38 0.13 
   Group x time x role       81 0.01 0.99 0.01 
Patient general distress  2.64 (0.50) 2.97 (0.53) 2.62 (0.53) 3.20 (0.50) 2.40 (0.55) 3.43 (0.54)     
Caregiver general distress 4.12 (0.46) 3.83 (0.50) 3.43 (0.50) 4.12 (0.46) 5.06 (0.52) 3.71 (0.52)     
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   Group       46 0.52 0.47 0.11 
   Time       76 0.66 0.52 0.09 
   Role       42 18.41 0.00 0.55 
   Time x role       80 2.87 0.06 0.19 
   Group x time       76 0.16 0.85 0.05 
   Group x role       42 0.19 0.67 0.07 
   Group x time x role       80 3.68 0.03 0.21 
Secondary Outcomes:           
Patient fatigue 10.56 (0.83) 10.83 (0.89) 10.38 (0.89) 10.04 (0.83) 9.99 (0.92) 10.43 (0.92)     
   Group       51 0.17 0.68 0.06 
   Time       82 0.03 0.98 0.02 
   Group x time       82 0.30 0.74 0.06 
Patient pain intensity 6.64 (0.55) 6.46 (0.58) 6.31 (0.58) 6.36 (0.55) 6.22 (0.59) 6.32 (0.59)     
   Group       49 0.05 0.82 0.03 
   Time       78 0.22 0.80 0.05 
   Group x time       78 0.14 0.87 0.04 
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Patient sleep disturbance 10.56 (0.71) 10.24 (0.78) 10.04 (0.78) 11.24 (0.71) 10.15 (0.81) 9.85 (0.81)     
   Group       44 0.02 0.88 0.02 
   Time       74 1.64 0.20 0.15 
   Group x time       74 0.38 0.69 0.07 
Patient breathlessness 1.08 (0.19) 1.16 (0.21) 1.19 (0.21) 1.05 (0.19) 0.84 (0.22) 0.69 (0.22)     
   Group       49 1.40 0.24 0.17 
   Time       80 0.37 0.69 0.07 
   Group x time       80 1.32 0.27 0.13 
Patient struggle with illness  12.24 (0.97) 11.81 (0.99) 11.26 (0.99) 13.00 (0.97) 12.67 (1.01) 12.30 (1.01)     
Caregiver struggle with 
illness  
13.64 (0.77) 11.95 (0.80) 12.10 (0.80) 13.80 (0.77) 13.74 (0.82) 13.12 (0.82)     
   Group       49 0.80 0.38 0.13 
   Time       77 5.68 0.01 0.26 
   Role       50 2.15 0.15 0.20 
   Time x role       79 0.58 0.56 0.09 
   Group x time       77 1.12 0.33 0.12 
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   Group x role       50 0.01 0.93 0.01 
   Group x time x role       79 1.40 0.25 0.13 
Patient illness acceptance 17.28 (0.60) 17.30 (0.62) 17.75 (0.62) 16.60 (0.60) 16.15 (0.64) 16.03 (0.63)     
Caregiver illness acceptance 15.64 (0.67) 15.96 (0.70) 16.31 (0.70) 14.68 (0.67) 14.90 (0.71) 15.67 (0.71)     
   Group       51 1.96 0.17 0.19 
   Time       78 2.34 0.10 0.17 
   Role       49 8.15 0.01 0.38 
   Time x role       77 2.69 0.07 0.18 
   Group x time       78 0.44 0.64 0.08 
   Group x role       49 0.10 0.75 0.05 
   Group x time x role       77 1.70 0.19 0.15 
Note. ACT = Acceptance and Commitment Therapy; Mean = Estimated marginal means; SE = standard error; Pr = partial correlation.  
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Figure Caption 
Figure 1. Study CONSORT diagram 
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• Patient withdrawn for any reason (n=3)
• Caregiver ineligible due to medical reasons 
(n=1)
Patients withdrawn (n=6)
• Medical reasons (n=2) 
• Death (n=1)
• Lost to follow-up (n=2)
• Caregiver withdrawn for any reason (n=1)
Patients missed follow-up (n=1)
Caregivers withdrawn (n=6)
• Lack of interest (n=1) 
• Lost to follow-up (n=2)
• Patient withdrawn for any reason (n=3)
Caregivers missed follow-up (n=1)
Patients withdrawn (n=1)
• Lack of interest (n=1) 
Caregivers withdrawn (n=1)
• Lack of interest (n=1)
Number of sessions completed:
0    n=2 dyads
1 n=2 dyads
2    n=1 dyad
3    n=0 dyads
4    n=0 dyads 
5    n=0 dyads 
6    n=20 dyads
Number of sessions completed:
0    n=1 dyad
1 n=2 dyads
2    n=1 dyad
3    n=0 dyads
4    n=1 dyad
5    n=1 dyad
6    n=19 dyads
Allocation
